Pfizer Inc. $PFE Shares Sold by Renasant Bank

Renasant Bank trimmed its position in Pfizer Inc. (NYSE:PFE) by 66.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 15,215 shares of the biopharmaceutical company’s stock after selling 30,667 shares during the period. Renasant Bank’s holdings in Pfizer were worth $379,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in PFE. Horizon Financial Services LLC grew its position in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares during the period. YANKCOM Partnership purchased a new position in Pfizer in the 4th quarter valued at about $28,000. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer in the 3rd quarter worth about $29,000. True Wealth Design LLC boosted its holdings in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer in the 2nd quarter worth about $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 0.8%

Shares of NYSE PFE opened at $26.27 on Thursday. The firm has a market cap of $149.36 billion, a price-to-earnings ratio of 19.31 and a beta of 0.43. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52-week low of $21.97 and a 52-week high of $28.75. The business’s 50 day moving average is $27.17 and its two-hundred day moving average is $26.09.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 earnings per share. Research analysts predict that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s payout ratio is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage win for ELREXFIO (elranatamab) — the Phase 3 MagnetisMM‑5 study met its primary endpoint (statistically significant improvement in progression‑free survival) for relapsed/refractory multiple myeloma, strengthening Pfizer’s oncology pipeline and potential future revenue. Pfizer’s blood cancer drug meets main goal in late-stage trial
• Positive Sentiment: Vyndamax patent settlements extend effective exclusivity until 2031 — the deals delay generic entry and preserve revenue prospect for Pfizer’s ~$6.4B heart‑disease franchise in the U.S., reducing near‑term downside from generic competition. Pfizer protects $6.4bn heart disease blockbuster from generics, for now
• Neutral Sentiment: Analysts show mixed views — coverage pieces note conflicting analyst sentiment on Pfizer (and peers), reflecting divergence on growth prospects vs. income appeal; this keeps trading rangey as investors await clearer catalysts. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: Sector tailwind: clinical trials market projected to grow strongly through 2034, supporting long‑term demand for Pfizer’s R&D and late‑stage assets — a structural positive but not an immediate catalyst. Clinical Trials Market Analysis/Forecasts 2026-2034
• Negative Sentiment: Modest analyst estimate cut — Erste trimmed FY2027 EPS forecasts slightly, keeping consensus below prior levels; even small downgrades can weigh on a high‑dividend name when growth is in focus. Erste cuts FY2027 estimates for Pfizer
• Negative Sentiment: Dividend/valuation debate and investor rotation — commentary urging investors to favor growth over high‑yield pharma and recent profit‑taking have pressured shares, contributing to the intraday decline despite positive pipeline and patent news. Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Barclays began coverage on shares of Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price on the stock. HSBC raised their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, CICC Research assumed coverage on shares of Pfizer in a research report on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average price target of $28.74.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.